• Explore /
  • Poster
  • / Phase I dose-escalation study of <sup>225</sup>Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Scott Tagawa

Scott T. Tagawa

Weill Cornell Medical College, New York, NY

Scott T. Tagawa , Shankar Vallabhajosula , Yuliya Jhanwar , Karla V. Ballman , Amy Hackett , Lauren Emmerich , John Babich , A. Oliver Sartor , Lauren Christine Harshman , Himisha Beltran , Ana M. Molina , David M. Nanus , Neil Harrison Bander

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03276572

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS399)

DOI

10.1200/JCO.2018.36.6_suppl.TPS399

Abstract #

TPS399

Poster Bd #

M19

Abstract Disclosures

Similar Posters

First Author: Scott T. Tagawa

First Author: Scott T. Tagawa

First Author: Scott T. Tagawa

First Author: Michael Sun